Latest news with #TranscriptaBio
Yahoo
30-05-2025
- Health
- Yahoo
Transcripta Bio collaborates with Microsoft Research to Advance AI-Driven Disease-Gene Discovery
PALO ALTO, Calif., May 30, 2025 /PRNewswire/ -- Transcripta Bio today announced a research collaboration with Microsoft Research to accelerate the discovery of disease-gene associations using advanced artificial intelligence (AI) and large-scale transcriptomic data. This collaboration brings together Transcripta Bio's proprietary Drug-Gene Atlas, which contains over a billion gene responses and full-transcriptome data, and Microsoft Research's machine learning expertise with the goal of identifying novel therapeutic opportunities faster and with more certainty than conventional methods. Transcripta Bio and Microsoft Research will analyze chemotranscriptomic datasets with a primary goal to identify candidate disease-gene associations supported by experimental evidence of gene expression modulation. The teams hope to accelerate the path from discovery to clinical candidate selection, with the potential for fast-tracking and delivering new therapies to patients more efficiently. Scott Saponas, Senior Director and Deputy Lab Director, Microsoft Research Health Futures, stated: "We are excited to collaborate with Transcripta Bio to leverage our expertise in rare disease genomics and AI, aiming to develop innovative methods for drug discovery that can significantly impact the treatment of rare diseases." Dr. Chris Moxham, Co-founder and CEO of Transcripta Bio, commented: "This collaboration with Microsoft Research enables us to scale our transcriptomics-driven approach, leveraging Microsoft's computational resources and AI expertise. Together, we are setting a new standard for the speed, certainty, and efficiency of drug discovery." About Transcripta Bio Transcripta Bio is an AI drug discovery company specializing in transcriptomics-driven insights to identify and develop novel therapeutics across multiple disease areas. Using its proprietary AI platform, Transcripta Bio accelerates the discovery and validation of promising drug candidates, leveraging both repurposed and novel molecules for targeted therapeutic interventions. Website: Media Contact: press@ View original content to download multimedia: SOURCE Transcripta Bio
Yahoo
25-03-2025
- Business
- Yahoo
SOLVE FSHD Announces Strategic Collaboration with Transcripta Bio to Advance Drug Discovery for FSHD
VANCOUVER, British Columbia, March 25, 2025--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), is pleased to announce a strategic collaboration with Transcripta Bio, a cutting-edge AI-driven drug discovery company. This collaboration will focus on leveraging Transcripta Bio's advanced drug screening platform to identify and develop promising therapeutic candidates for FSHD, a debilitating muscular disorder affecting approximately 38,000 individuals in the U.S. alone. Under this agreement, SOLVE FSHD will provide strategic funding to support a drug screening initiative led by Transcripta Bio. The project will analyze a broad range of approved and late-stage clinical compound libraries in FSHD cell lines for their potential efficacy in targeting fibro-adipogenic progenitor (FAP) cells, known to contribute to the disease pathology. This initiative represents a significant step forward in drug repurposing for the disease with a novel target space, offering a faster path to clinical translation and one of the first dedicated efforts to systematically explore repurposed drugs for FSHD. "This collaboration aligns perfectly with SOLVE FSHD's mission to de-risk and accelerate therapeutic development for FSHD," said Eva Chin, Executive Director of SOLVE FSHD. "By partnering with Transcripta Bio, we are not only leveraging state-of-the-art AI-driven drug discovery but also working with a team who has the experience and expertise to ensure that the best potential candidates are rapidly validated and prepared for clinical trials, while going after a novel approach to attenuate muscle fibrosis." Through this partnership, both organizations will work together to evaluate promising drug candidates using advanced transcriptomics and data-driven insights. The collaboration aims to accelerate the identification of potential treatments and advance them toward clinical testing as efficiently as possible. Transcripta Bio will lead the advancement and commercialization of promising candidates into the clinic. "We are excited to collaborate with SOLVE FSHD on this important initiative," said Transcripta Bio CEO Chris Moxham. "Our platform has been successful in identifying novel drug candidates across multiple therapeutic areas, and we are eager to apply our technology to accelerate FSHD drug development." This partnership underscores SOLVE FSHD's commitment to funding high-impact, innovative approaches to address the urgent unmet need for FSHD therapies by 2027. By harnessing Transcripta Bio's AI-driven approach, the partnership has the potential to identify fast-tracked, repurposed drug candidates that could reach patients sooner than traditional drug development pathways. About SOLVE FSHDSOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, widely known as the founder and part owner of various technical apparel companies including lululemon and Amer Sports, which holds brands such as Arc'teryx, Salomon and Wilson Sports. The Wilson family has committed $100 million to kick-start funding into projects that support the organization's mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD. About Transcripta BioTranscripta Bio is an AI drug discovery company specializing in transcriptomics-driven insights to identify and develop novel therapeutics across multiple disease areas. Using its proprietary AI platform, Transcripta Bio accelerates the discovery and validation of promising drug candidates, leveraging both repurposed and novel molecules for targeted therapeutic interventions. View source version on Contacts Media Contact: Andrea MestrovicVery Polite Agencyandrea@ Sign in to access your portfolio
